Ongoing treatment(s)-Biological therapy-Targeted Therapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Biological therapy-Targeted Therapy Posts on Medivizor

Second cancers in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the occurrence of second cancers in patients with chronic myeloid leukemia (CML). This study concluded that the occurrence of overall second cancers in these patients is slightly higher than that of the general population. Some background Tyrosine kinase inhibitors (TKIs) are commonly used for the...

Read More

Kidney problems and anemia linked with imatinib use in chronic myeloid leukemia

Posted by on Feb 20, 2019 in Leukemia | 0 comments

In a nutshell This study looked at the effect of imatinib (Gleevec) on kidney function in patients with chronic myeloid leukemia (CML). Researchers found that a reversible decline in kidney function was linked with long-term imatinib use in these patients. Some background Imatinib is a strong drug used to treat CML. The kidney produces a hormone that...

Read More

Serious infections in patients receiving ibrutinib for treatment of leukemia and lymphoma

Posted by on Sep 27, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the risk of infections associated with ibrutinib (Imbruvica) used in the treatment of leukemia and lymphoma. Researchers found that patients receiving ibrutinib are at risk of serious infections. Some background Ibrutinib is a drug which targets certain proteins on cancer cells to stop them from working. It is often...

Read More

Comparing chemoimmunotherapy and ibrutinib treatment in patients with chronic lymphocytic leukemia

Posted by on Sep 7, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to compare the outcomes of patients with chronic lymphocytic leukemia who received chemoimmunotherapy or ibrutinib. This study suggested that ibrutinib may have more favorable outcomes for these patients when compared to chemoimmunotherapy. Some background Chemoimmunotherapy (CIT) is a treatment option that can be used...

Read More

Survival and risk factors of developing lung fluid in patients with leukemia treated with dasatinib

Posted by on Aug 24, 2018 in Leukemia | 0 comments

In a nutshell This study looked at the risk and outcomes of fluid build-up around the lungs in patients with leukemia receiving dasatinib (Sprycel) treatment. The study found that age was a risk factor for developing lung fluid in these patients but overall survival was not affected. Some background Leukemia is a cancer of the bone marrow that leads...

Read More

Evaluating vascular safety of TK inhibitors in patients with chronic myeloid leukemia

Posted by on Aug 18, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the vascular (blood vessels) side effects associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML). This study concluded that patients treated with nilotinib (Tasigna) experienced more vascular side effects. Some background Tyrosine kinase (TK) inhibitors are the standard therapy...

Read More

Drug interactions with tyrosine kinase inhibitors in chronic myeloid leukemia

Posted by on Jul 17, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the interactions between tyrosine kinase inhibitors and other drugs taken at the same time in patients with chronic myeloid leukemia. This study concluded that drug interactions were found in a significant number of patients, with mild side effects. Some background Imatinib (Gleevec) and similar drugs are the...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...

Read More